Q3 2023 13F Holders as of 30 Sep 2023
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
50,580,036
-
Total 13F shares
-
36,263,336
-
Share change
-
+1,817,694
-
Total reported value
-
$349,220,972
-
Put/Call ratio
-
38%
-
Price per share
-
$9.63
-
Number of holders
-
101
-
Value change
-
+$17,907,372
-
Number of buys
-
49
-
Number of sells
-
35
Institutional Holders of KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (KALV) as of Q3 2023
As of 30 Sep 2023,
KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (KALV) was held by
101 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
36,263,336 shares.
The largest 10 holders included
TANG CAPITAL MANAGEMENT LLC, TCG Crossover Management, LLC, Frazier Life Sciences Management, L.P., VR Adviser, LLC, SUVRETTA CAPITAL MANAGEMENT, LLC, Saturn V Capital Management LP, VANGUARD GROUP INC, Boxer Capital, LLC, BlackRock Inc., and ADAGE CAPITAL PARTNERS GP, L.L.C..
This page lists
101
institutional shareholders reporting positions in this security
for the Q3 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.